Dogwood Therapeutics Inc DWTX 深 沪
已收盘 07-02 16:00:00 美东时间
1.49
-0.010
-0.67%
华盛通- 最 高1.61
- 今 开1.54
- 成交量 10.78万股
- 最 低 1.45
- 昨 收 1.50
- 总市值 5010.80万
- 52周最高 9.50
- 市盈率 静 --
- 换手率 0.32%
- 52周最低 1.28
- 委 比 21.03%
- 总股本 3362.96万
- 历史最高 417.75
- 量 比 1.16
- 振 幅 10.67%
- 历史最低 1.28
- 每 手 1
- 风险率 1.74%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Dogwood Therapeutics names OrbiMed’s Iain Dukes chair of new scientific advisory board
Dogwood Therapeutics names OrbiMed’s Iain Dukes chair of new scientific advisory board Dogwood Therapeutics named OrbiMed venture partner Iain Dukes chair of its newly formed Scientific Advisory Board. Dukes will advise leadership on scientific strategy for pain and neuropathy programs, including Ha
06-30 20:45
Dogwood Therapeutics posts corporate presentation on non-opioid pain, neuropathy drug pipeline
Dogwood Therapeutics posts corporate presentation on non-opioid pain, neuropathy drug pipeline Dogwood Therapeutics highlighted Halneuron injection for chemotherapy-induced neuropathic pain, targeting a Phase 2b data readout in fall 2026. Milestones include a Q4 2026 end-of-Phase 2 FDA submission fo
06-12 21:43
Dogwood Therapeutics Starts New Halneuron Hemotherapy Induced Neuropathic Pain Phase 2b Extension Trial
Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("Dogwood" or the "Company"), a biopharmaceutical company developing first-in-class, non-opioid medicines to treat pain and neuropathy, today announced commencement of a new
05-18 20:48
Dogwood Therapeutics launches 12-week Halneuron Phase 2b CINP extension trial
Dogwood Therapeutics launches 12-week Halneuron Phase 2b CINP extension trial Dogwood Therapeutics launched a Phase 2b open-label extension study of Halneuron for chemotherapy-induced neuropathic pain, enrolling patients who complete its ongoing 4-week double-blind trial. Results from the extension
05-18 20:45
Dogwood Therapeutics Q1 net loss narrows, no revenue reported
Dogwood Therapeutics Q1 net loss narrows, no revenue reported Overview U.S. biopharma developer reported no Q1 revenue, net loss narrowed from prior year Q1 R&D and G&A expenses rose due to increased drug development and personnel costs Company announced global partnership for legacy antiviral asset
05-14 20:38
Dogwood Therapeutics Q1 EPS $(0.15), Inline
Dogwood Therapeutics (NASDAQ:DWTX) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate. This is a 98.22 percent increase over losses of $(8.45) per share from the same period last
05-14 20:31
Earnings Scheduled For May 14, 2026
Companies Reporting Before The Bell • Urban One (NASDAQ:UONEK) is expected to r...
05-14 19:11
美股大行评级 | 美银大幅上调西部数据、希捷科技目标价！宝洁、Baker Hughes、Flagstar Bank、斯伦贝谢等获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从48美元升至49美元；Chardan Capital：维持Intellia Therapeutics"买入"评级，目标价从27美元升至30美元
04-28 10:07
Dogwood Therapeutics Partners With PRIDCor Therapeutics To Advance Its Anti-Viral Candidates IMC-1 And IMC-2
Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("Dogwood" or the "Company"), a company that focuses on developing new medicines to treat pain and neuropathy, today announced a global development and commercialization
04-23 21:07
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Psyence Biomedical (NASDAQ:PBM) shares increased by 63.4% to $9.59 dur...
04-17 05:05
